Search Results

BACKGROUND: These days the Hepatitis B virus (HBV) DNA quantitation is the common tool for defining the viral replication state and antiviral therapeutic effect. However, it has a slow turn around time due to a labour intensive complex procedure. The HBeAg assay is a simple, rapid test, but it gives only qualitative information. However, Elecsys 2010 immunoanalyzer (Roche Diag-nostics GmbH, Germany) gives not only qualitative information but also semiquantitative information. So, we want to know about the clinical utility of HBeAg semiquantitation on Elecsys 2010. METHODS: HBeAg and HBV DNA were measured serially for 18 months by Elecsys 2010 and the Hybrid Capture System (HCS; Digene Corporation, Gaithersburg, USA) respectively to evaluate their general correlations (n=287) and serial-changing patterns after lamivudine treatment (n=30, 12-18 months) in 41 patients positive for HBeAg and HBV DNA. RESULTS: Positive correlation was found between the semiquantitative results of HBeAg and the quantitative results of HBV DNA (R=0.56, P<0.05). At two and five months after lamivudine treatment, significant differences (P<0.05) between HBV DNA disappearance groups (group 2, 3) and the HBV DNA remnant group (group 4) were found in the HBeAg level and a decreasing rate. The serial HBeAg and HBV DNA level and the decreasing rate showed a similar pattern in the HBV DNA disappearance groups (group 2, 3). However, a markedly delayed decreasing pattern in the HBeAg level was observed in the HBV DNA remnant group, when compared with HBV DNA. CONCLUSIONS: HBeAg semiquantitation using Elecsys 2010 would provide a cost effective, fast and valuable, and supplementary monitoring tool when the result might be reported in quantity in a dynamic range, because HBeAg semiquantitation could provide an outline of the HBV replication state HBeAg positive patients and a therapeutic predictive value in HBeAg positive, lamivudine treated patients.
DNA ; Hepatitis B e Antigens ; Hepatitis B virus* ; Humans ; Lamivudine*

1.Significance of serum HBeAg in serum HBsAg-positive glomerulonephritis.

2.Effect of the mutation in the carboxyl-terminal processing site of the hepatitis B virus core antigen on the HBeAg secretion.

3.The Clinical significance of HBV markers in chronic HBsAg carrier: Titers of HBsAg, and HBeAg, and presence or absence of HBeAg and HBV-DNA.

4.A study on the relationship between HBeAg and hepatitis B virus DNAamong healthy HBsAg carries.

5.Quantitative determination for HBeAg: in clinical practice and potential future applications.

6.Natural history of chronic Hepatitis B viral infection in Viet Nam

7.Semiquantitative Measurement of Hepatitis B Virus e Antigen by Elecsys 2010 Immunoanalyzer in Lamivudine Treated Patients.

8.Dealing with HBeAg negative chronic hepatitis B.

9.Clinical Significance and Natural History of "HBeAg Negativity" in Patients with Chronic HBV Infection.

10.A Study on Hepatitis B Surface Antigen in Tear of Hepatitis Patients.

Display Mode

Output Records

File Type